VivoSeq
Psychiatry

Eating Disorder

48

Pipeline Programs↗

9

Active Trials↗

28

Companies Involved↗

Eating Disorder is a moderately active landscape with 48 programs across 28 companies. The most active players are Retrophin, Teva, Lykos Therapeutics. 12 therapies are approved with 11 more in late-stage development.

Intelligence

Pipeline Metrics

Competitive Density

60/100

Pipeline Velocity

19/100

Mech. Concentration

8/100

Completion Rate

92/100

Attrition Rate

7/100

Competition

Competitive Landscape

Bubble size = clinical trials

Approved
Phase 3
Phase 2
Phase 1
Preclinical

Key Players

Top Companies Companies ranked by the number of pipeline programs they run for this disease.

R

Retrophin

1 program

Phase 1Teva logo

Teva

1 program

Phase 1L

Lykos Therapeutics

1 program

Phase 2Idorsia Pharmaceuticals Ltd. logo

Idorsia Pharmaceuticals Ltd.

1 program

Phase 2T

TRYP Therapeutics

1 program

Phase 2Otsuka logo

Otsuka

1 program

Phase 2

Pipeline

Programs by Phase

Analysis

Modality Breakdown

96%

Small molecule

49 of 51 classified programs — the dominant modality here.

4%ALL OTHERSPeptide24%

Small molecule leads; the ring shows all 51 classified programs, each share of the total. Modality classified for 100% of 56 pipeline programs.

Analysis

Trial Status

61

clinical trials

Completed44 · 72%
Recruiting5 · 8%
Unknown status4 · 7%
Withdrawn3 · 5%
Not yet recruiting2 · 3%
Enrolling by invitation2 · 3%
Other1 · 2%

Clinical Trials

Trial Activity

61 trials

The Role of Estrogen in the Neurobiology of Eating Disorders
Recruiting·MMassachusetts General Hospital·Phase 2·NCT03740204·120 enrolled
Elucidating TAAR-1, Dopamine, and Norepinephrine in Binge Eating Disorder Using Solriamfetol
Recruiting·AAxsome Therapeutics, Inc.·Phase 3·NCT06413433·450 enrolled
Naltrexone Neuroimaging in Teens With Eating Disorders
Recruiting·—·Phase 1·NCT05509257·60 enrolled
A Study of the Effects of Oxytocin in Adults With Binge-eating Disorder
Recruiting·MMassachusetts General Hospital·Phase 2·NCT05664516·60 enrolled
Efficacy and Safety of Tirzepatide Versus Placebo or Lisdexamfetamine Dimesylate for Binge-Eating Disorder
Recruiting·JJohns Hopkins University·Phase 2·NCT06847399·105 enrolled
Sleep and Activity For Eating Disorders
Not yet recruiting·—·N/A·NCT07295470·75 enrolled
A Study on the Effects of Combined FMT on Gut Microbiota and Eating Disorder Symptoms in AN
Not yet recruiting·SShanghai Mental Health Center·N/A·NCT06744751·30 enrolled
Ketamine Effects on Learning In Eating Disorders
Enrolling by invitation·—·Phase 2·NCT06736769·20 enrolled
Open-Label Safety Study of Solriamfetol in Subjects With Binge Eating Disorder
Enrolling by invitation·AAxsome Therapeutics, Inc.·Phase 3·NCT06878976·300 enrolled
A Study of the Effectiveness and Safety of Topiramate in the Treatment of Moderate to Severe Binge-eating Disorder Associated With Obesity
Completed·Johnson & Johnson Pharmaceutical Research & Development, L.L.C. logoJohnson & Johnson Pharmaceutical Research & Development, L.L.C.·Phase 2/3·NCT00210808·407 enrolled
Zonegran in the Treatment of Binge Eating Disorder Associated With Obesity
Completed·LLindner Center of HOPE·Phase 3·NCT00221442·60 enrolled
An Efficacy and Tolerability Study for Topiramate in Obese Patients With Binge Eating Disorder.
Completed·Johnson & Johnson logoJohnson & Johnson·Phase 3·NCT00307619·73 enrolled
Study of Duloxetine vs Placebo in Treatment of Binge Eating Disorder With Depression
Completed·UUniversity of Cincinnati·Phase 4·NCT00607789·40 enrolled
Treatment of Binge Eating Disorder in Obesity: Naltrexone/ Bupropion Combination Versus Placebo
Completed·YYale University·N/A·NCT02317744·22 enrolled
Topiramate for the Treatment of Alcohol Dependent Binge-Eating Disordered Individuals
Completed·UUniversity of Virginia·Phase 2·NCT00300742·5 enrolled
Page 1 of 5

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)